Treat-to-target approach in the management of inflammatory Bowel disease.
Biomarcadores
Biomarkers
Colitis ulcerosa
Crohn's disease
Enfermedad de Crohn
Monitoring
Monitorización
Tratamiento por objetivos
Treat-to-target
Ulcerative colitis
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
23
05
2020
accepted:
29
06
2020
pubmed:
20
10
2020
medline:
5
11
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
With the advent of biologic and small molecule therapies, there has been a substantial change in the treatment of inflammatory bowel disease. These advances have had a great impact in preventing disease progression, intestinal damage and, therefore, have contributed to a better quality of life. Discordance between symptom control and mucosal healing has been demonstrated. This has led to the search for new disease control targets. The treat to target strategy, based on expert recommendations and now a randomized controlled trial, has determined that clinical and endoscopic remission should be the goal of therapy. Biomarkers (fecal calprotectin) can be a surrogate target. Although histological healing has shown benefits, there is inadequate evidence and inadequate therapy for that to be a fixed goal at this time. This review will focus on therapeutic goals, according to the evidence currently available, and evaluate strategies to achieve them.
Identifiants
pubmed: 33070988
pii: S0210-5705(20)30318-6
doi: 10.1016/j.gastrohep.2020.06.032
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
312-319Informations de copyright
Copyright © 2020 Elsevier España, S.L.U. All rights reserved.